Responsibility

Responsible business

At GSK, we’re guided by our purpose to unite science, technology and talent to get ahead of disease together. We deliver this purpose considering the social, environmental and governance impacts across everything we do, from the lab to the patient.

Scroll to explore

Our approach to being a responsible company

Our six areas of focus

We've identified six areas of responsible business that matter most to us: pricing and access; global health and health security; inclusion; environmental sustainability; product governance and ethical standards.

Pricing and access
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
Inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
Environmental sustainability
We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.
Product governance
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
Ethical standards
Our culture guides our people to do the right thing and act on any concerns they have.

Latest news

Putting health at the centre of action on climate and nature

Report

Putting health at the centre of action on climate and nature

Environmental Action Report 2022

Read our Environmental Action Report 2022 and learn how we ensure that the solutions for climate change and nature loss are also drivers of human health.

We are determined to show what’s possible through what we do and how we partner, and by using our voice to put health firmly at the centre of action on climate and nature.

Public policy and patient advocacy

External article

GSK to invest £1 billion in infectious disease battle

View article on Bloomberg
23 June 2022

We've announced ambitious commitments, including £1bn investment over ten years to accelerate R&D into infectious diseases that disproportionately impact lower-income countries.

Find out how our Global health unit will focus on impact.

_